[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

193

1 are many other potential therapies and many other
2 important lines of research that are going to be
3 competing for funding.
4 And so we have structured our thinking
5 that way, as: first, what are the criteria? Do any
6 products meet it? And then, third, is this a priority
7 for research?
8 It might be helpful if there were some
9 parallel analysis going on.
10 CO-CHAIRMAN FAUCI: Very good point, Don.
11 That was really one of the reasons why when I started
12 off the discussion after the break, I said we should
13 look at it.
14 I mean, if we really wanted to look at it
15 in a vacuum from a pure scientific standpoint, you
16 have essentially reiterated what I said. From a pure
17 scientific standpoint, should you go ahead based on a
18 certain amount of data? And what is the further
19 information that you need to make that decision? So
20 I think there's an agreement there.
21 The discussion we brought to the next
22 step, which was given the very special circumstances,
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]